Project 4: NOX1 Involvement In Colon Cancer
Project 4: NOX1 Involvement In Colon Cancer
批准号:
7511070
负责人:
John David Lambeth
金额:
$13.57万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-07-01 至 2013-06-30
关键词:
1-Phosphatidylinositol 3-KinaseAgeAnimalsApoptosisCause of DeathCell modelCellsCessation of lifeColon CarcinomaColon, RectumColorectal NeoplasmsDNA DamageEnzymesEventFamilyGenetic TranscriptionGrowthHumanIntestinal CancerIntestinal NeoplasmsIntestinesKnock-outKnockout MiceLinkMAPK8 geneMalignant NeoplasmsMalignant neoplasm of gastrointestinal tractMediatingMitosisMolecularMusMutationNADPH OxidaseNF-kappa BNeoplasmsNormal tissue morphologyOncogenicOxidantsOxidative StressPathway interactionsPlayPopulationProtein OverexpressionProtein Tyrosine PhosphataseProtein p53Reactive Oxygen SpeciesRoleSignal PathwaySignal TransductionSourceStressSystemTP53 geneTestingTissuesTyrosine PhosphorylationUnited Statesangiogenesisbasegenetic regulatory proteinintestinal epitheliummouse modelmutantnovelresponsetranscription factortumortumor initiationtumorigenesisvillin
中文摘要
NOX1氧化应激、RAS与结肠癌
NADPH-氧化酶Nox1产生活性氧(ROS),通过信号转导发挥作用
激活有丝分裂生长和血管生成的途径。Nox1在早期人类中过表达-60%-70%
结肠癌,与肿瘤发生中的作用一致。基于细胞模型研究,我们假设
人类结肠癌中Nox1的过度表达可能是由激活的KRAS诱导Nox1转录所致。
人类肠道肿瘤与对照组织的特征将确定Nox1
过表达与K-RAS的致癌突变和/或肿瘤中的失活突变有关
抑制基因P53和ARC。肿瘤中Nox1过度表达与NFkappaB的关系
生长相关信号通路(MARK、PI3-)的激活、COX2过表达和激活
也将对其进行评估。直接评价K-RAS致癌因素之间的因果关系
突变、Nox1过表达和肠癌,我们之前发现Nox1过表达和
Nox1基因敲除小鼠。将Villin K-RasV12小鼠与Nox1基因敲除和Nox1过表达的小鼠杂交
动物,我们将测试Nox1是否介导V12-RAS导向的肿瘤发生。通过调查Nox1
肿瘤抑制基因(P53和ARC)的表达、突变和生长相关信号的激活
在肿瘤和邻近正常组织中的信号转导途径(Akt/PKB、ERK1、2、JNK),我们将确定分子事件
与肿瘤的发生和发展有关。Nox1调节有丝分裂生长的机制将
通过评估核因子-kappaB的激活和COX2的诱导/激活来进一步研究。我们会
与其他项目合作评估Nox1在诱导DNA损伤反应中的作用
肿瘤的启动/进展途径。我们还将调查NOX1衍生的ROS的假设
通过抑制蛋白酪氨酸磷酸酶刺激有丝分裂生长,导致酪氨酸增加
重要的促有丝分裂调节蛋白的磷酸化水平。这些研究将为我们提供新的
关于Nox1在胃肠癌中的作用及其与肿瘤基因突变的关系的信息
K-RAS,以及RAS和NOX1利用的促有丝分裂信号系统。
英文摘要
Nox1 Oxidant Stress, Ras And Colon Cancer"
The NADPH-oxidase Nox1 generates reactive oxygen species (ROS) that function through signaling
pathways to activate mitogenic growth and angiogenesis. Nox1 is overexpressed in -60-70% of early human
colon cancers, consistent with a role in tumorigenesis. Based on cell model studies, we hypothesize that
Nox1 overexpression in human colon cancers can result from induction of Nox1 transcription by activated KRas.
Human intestinal tumors vs. control tissue will be characterized to establish whether Nox1
overexpression is linked to oncogenic mutations in K-Ras and/or to inactivating mutations in the tumor
suppressors p53 and ARC. The extent to which Nox1 overexpression in tumors is associated with NFkappaB
activation, Cox2 overexpression and activation of growth-related signaling pathways (MARK, PI 3-
kinase) will also be evaluated. To evaluate directly the causal relationships among K-Ras oncogenic
mutation, Nox1 overexpression, and intestinal cancer, we previously developed Nox1-overexpressing and
Nox1 -knockout mice. By crossing villin K-RasV12 mice with Nox1-knockout and Nox1-overexpressing
animals, we will test whether Nox1 mediates V12-Ras-directed tumorigenesis. By investigating Nox1
expression, mutation of tumor suppressors (p53 and ARC) and activation of growth-associated signaling
pathways (Akt/PKB, ERK1,2, JNK) in tumors and adjacent normal tissue, we will determine molecular events
relevant to tumor initiation and progression. The mechanisms by which Nox1 regulates mitogenic growth will
be further investigated by evaluating activation of NF-kappaB and the induction/activation of Cox2. We will
evaluate collaboratively with other projects the role of Nox1 in the induction of the DNA damage response in
the tumor initiation/progression pathway. We will also investigate the hypothesis that Nox1-derived ROS
stimulates mitogenic growth by inhibiting protein tyrosine phosphatases, leading to a increased tyrosine
phosphorylation levels of important mitogenic regulatory proteins. These studies will provide novel
information regarding the role of Nox1 in gastrointestinal cancers, its relationship to oncogenic mutations in
K-Ras, and the mitogenic signaling systems utilized by Ras and Nox1.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NOX1 and NOX2 as Therapeutic Targets in Influenza
-
批准号:8889190
-
项目类别:
-
资助金额:$45.96万
-
财政年份:2012
-
负责人:John David Lambeth
-
依托单位:
NOX1 and NOX2 as Therapeutic Targets in Influenza
-
批准号:8490301
-
项目类别:
-
资助金额:$22.54万
-
财政年份:2012
-
负责人:John David Lambeth
-
依托单位:
NOX1 and NOX2 as Therapeutic Targets in Influenza
-
批准号:8390976
-
项目类别:
-
资助金额:$19.28万
-
财政年份:2012
-
负责人:John David Lambeth
-
依托单位:
Project 4: NOX1 Involvement In Colon Cancer
-
批准号:8099689
-
项目类别:
-
资助金额:$13.83万
-
财政年份:2010
-
负责人:John David Lambeth
-
依托单位:
Mox 1: A Novel Mitogenic Oxidase
-
批准号:7811391
-
项目类别:
-
资助金额:$64.33万
-
财政年份:2009
-
负责人:John David Lambeth
-
依托单位:
Regulation of Nox Enzymes by Calcium and Novel Subunits
-
批准号:8066381
-
项目类别:
-
资助金额:$24.55万
-
财政年份:2004
-
负责人:John David Lambeth
-
依托单位:
Regulation of Nox Enzymes by Calcium and Novel Subunits
-
批准号:7069094
-
项目类别:
-
资助金额:$24.5万
-
财政年份:2004
-
负责人:John David Lambeth
-
依托单位:
Regulation of Nox Enzymes by Calcium and Novel Subunits
-
批准号:7419032
-
项目类别:
-
资助金额:$23.79万
-
财政年份:2004
-
负责人:John David Lambeth
-
依托单位:
Regulation of Nox Enzymes by Calcium and Novel Subunits
-
批准号:7239651
-
项目类别:
-
资助金额:$23.79万
-
财政年份:2004
-
负责人:John David Lambeth
-
依托单位:
Regulation of Nox Enzymes by Calcium and Novel Subunits
-
批准号:6817762
-
项目类别:
-
资助金额:$25.09万
-
财政年份:2004
-
负责人:John David Lambeth
-
依托单位:
Regulation of Nox Enzymes by Calcium and Novel Subunits
-
批准号:8449706
-
项目类别:
-
资助金额:$23.08万
-
财政年份:2004
-
负责人:John David Lambeth
-
依托单位:
Regulation of Nox Enzymes by Calcium and Novel Subunits
-
批准号:7887135
-
项目类别:
-
资助金额:$25.31万
-
财政年份:2004
-
负责人:John David Lambeth
-
依托单位:
Regulation of Nox Enzymes by Calcium and Novel Subunits
-
批准号:8247071
-
项目类别:
-
资助金额:$24.55万
-
财政年份:2004
-
负责人:John David Lambeth
-
依托单位:
Regulation of Nox Enzymes by Calcium and Novel Subunits
-
批准号:8658004
-
项目类别:
-
资助金额:$23.81万
-
财政年份:2004
-
负责人:John David Lambeth
-
依托单位:
Regulation of Nox Enzymes by Calcium and Novel Subunits
-
批准号:6913621
-
项目类别:
-
资助金额:$25.09万
-
财政年份:2004
-
负责人:John David Lambeth
-
依托单位:
Dual Oxidases (Duox): Enzymology & Biological Function
-
批准号:7057319
-
项目类别:
-
资助金额:$26.12万
-
财政年份:2003
-
负责人:John David Lambeth
-
依托单位:
Dual Oxidases (Duox): Enzymology & Biological Function
-
批准号:6891403
-
项目类别:
-
资助金额:$26.75万
-
财政年份:2003
-
负责人:John David Lambeth
-
依托单位:
Dual Oxidases (Duox): Enzymology & Biological Function
-
批准号:6742511
-
项目类别:
-
资助金额:$26.75万
-
财政年份:2003
-
负责人:John David Lambeth
-
依托单位:
Dual Oxidases (Duox): Enzymology & Biological Function
-
批准号:6594087
-
项目类别:
-
资助金额:$26.75万
-
财政年份:2003
-
负责人:John David Lambeth
-
依托单位:
MOX 1--A NOVEL MITOGENIC OXIDASE
-
批准号:6038184
-
项目类别:
-
资助金额:$25.46万
-
财政年份:2000
-
负责人:John David Lambeth
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
-
批准号:82505677
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.00万元
-
批准年份:2025
-
负责人:吕雨霏
-
依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
-
批准号:82574874
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2025
-
负责人:刘天华
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位: